利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

12 条记录 (耗时 0.027 秒)

    Treatment of systemic lupus erythematosus by down-regulating the autoimmune response to autoantigens
    1.
    发明申请
    Treatment of systemic lupus erythematosus by down-regulating the autoimmune response to autoantigens 审中-公开
    通过下调对自身抗原的自身免疫反应来治疗系统性红斑狼疮

    公开(公告)号：US20060030524A1

    公开(公告)日：2006-02-09

    申请号：US11179820

    申请日：2005-07-13

    申请人： Irun Cohen ,  Varda Rotter ,  Neta Erez ,  Johannes Herkel

    发明人： Irun Cohen ,  Varda Rotter ,  Neta Erez ,  Johannes Herkel

    IPC分类号： A61K48/00 ,  A61K38/17

    CPC分类号： C07K14/4746 ,  A61K38/00 ,  A61K39/00 ,  A61K2039/505 ,  C07K16/18 ,  C07K16/4241 ,  G01N33/564 ,  G01N2800/104

    摘要： Systemic lupus erythematosus (SLE) can be prevented or treated by down-regulating the autoimmune response to the C-terminal-DNA-binding domain of the p53 protein (p53) by an active principle selected from the group consisting of: (i) a peptide of, or comprising, the C-terminal DNA-binding domain of the p53 protein; (ii) a monoclonal antibody (mAb) specific for said domain of p53 (Ab1), and fragments thereof; (iii) an mAb specific for Ab1 (hereinafter Ab2), and fragments thereof; (iv) a peptide based on a complementarity determining region (CDR) of the heavy or light chain of said Ab1 or Ab2; (v) a DNA molecule coding for (i) and (iv) of for the variable region of said Ab1 and Ab2 of (ii) and (iii); and (vi) T cells specific for (i) to (iv), fragments thereof, T cell receptor (TCR) thereof and peptides comprising the variable region of said TCR. SLE can also be diagnosed by assaying for antibodies (Ab1) against the C-terminal DNA-binding domain of p53 or antibodies (Ab2) specific to the Ab1 antibodies.

    摘要翻译： 可以通过选自以下的活性成分下调对自身免疫应答p53蛋白（p53）的C末端-DNA结合结构域的自身免疫应答来防止或治疗系统性红斑狼疮（SLE）：（i） 或包含p53蛋白的C-末端DNA结合结构域的肽; （ii）对所述p53结构域（Ab1）特异的单克隆抗体（mAb）及其片段; （iii）Ab1（以下称Ab2）特异性的mAb及其片段; （iv）基于所述Ab1或Ab2的重链或轻链的互补决定区（CDR）的肽; （v）编码（i）和（iv）的（ii）和（iii）所述Ab1和Ab2的可变区的DNA分子; 和（vi）特异于（i）至（iv）的T细胞，其片段，T细胞受体（TCR）和包含所述TCR的可变区的肽。 也可以通过测定针对p53的C末端DNA结合结构域的抗体（Ab1）或Ab1抗体特异性抗体（Ab2）来诊断SLE。

    Immunogenic compositions for induction of anti-tumor immunity
    2.
    发明申请
    Immunogenic compositions for induction of anti-tumor immunity 失效
    用于诱导抗肿瘤免疫的免疫原性组合物

    公开(公告)号：US20050208065A1

    公开(公告)日：2005-09-22

    申请号：US11129359

    申请日：2005-05-16

    申请人： Irun Cohen ,  Varda Rotter ,  Roland Wolkowicz ,  Pedro Ruiz ,  Neta Erez-Alon ,  Johannes Herkel

    发明人： Irun Cohen ,  Varda Rotter ,  Roland Wolkowicz ,  Pedro Ruiz ,  Neta Erez-Alon ,  Johannes Herkel

    IPC分类号： A61K39/00 ,  A61K48/00 ,  A61P35/00 ,  A61P37/04 ,  C07K16/18 ,  C07K16/30

    CPC分类号： C07K16/30 ,  A61K39/00 ,  A61K2039/505 ,  A61K2039/51 ,  C07K16/18 ,  C07K2317/565 ,  C07K2317/73

    摘要： The invention relates to methods of inducing an anti-tumor immunity and/or inducing an immune responses to p53 in mammals. The methods comprise administering to a mammal an effective amount of at least one immunogen selected from the group consisting of: (i) a peptide based on a CDR of the heavy or light chain of an anti-p53 mAb, which peptide is capable of eliciting antibodies to p53; and (ii) a DNA molecule coding for the variable (V) region of an anti-p53 mAb in a suitable gene delivery vehicle. Preferably the immunogen is administered in the form of a pharmaceutical composition. Preferably the peptide is 7 to 30 amino acid residues in length and contains a sequence of the CDR2 or CDR3 of the heavy chain, or of the CDR3 of the light chain of an anti-p53 mAb.

    摘要翻译： 本发明涉及在哺乳动物中诱导抗肿瘤免疫和/或诱导对p53的免疫应答的方法。 所述方法包括向哺乳动物施用有效量的选自以下的至少一种免疫原：（i）基于抗p53mAb的重链或轻链的CDR的肽，所述肽能够引发 p53抗体; 和（ii）在合适的基因递送载体中编码抗p53mAb的可变（V）区的DNA分子。 优选地，免疫原以药物组合物的形式施用。 优选地，肽的长度为7至30个氨基酸残基并且包含重链的CDR2或CDR3的序列或抗p53mAb的轻链的CDR3的序列。

    Immunogenic compositions for induction of anti-tumor immunity
    3.
    发明授权
    Immunogenic compositions for induction of anti-tumor immunity 失效
    用于诱导抗肿瘤免疫的免疫原性组合物

    公开(公告)号：US07378092B2

    公开(公告)日：2008-05-27

    申请号：US11129359

    申请日：2005-05-16

    申请人： Irun R. Cohen ,  Varda Rotter ,  Roland Wolkowicz ,  Pedro Ruiz ,  Neta Erez-Alon ,  Johannes Herkel

    发明人： Irun R. Cohen ,  Varda Rotter ,  Roland Wolkowicz ,  Pedro Ruiz ,  Neta Erez-Alon ,  Johannes Herkel

    IPC分类号： A61K39/395 ,  A61K39/00

    CPC分类号： C07K16/30 ,  A61K39/00 ,  A61K2039/505 ,  A61K2039/51 ,  C07K16/18 ,  C07K2317/565 ,  C07K2317/73

    摘要： The invention relates to methods of inducing an anti-tumor immunity and/or inducing an immune responses to p53 in mammals. The methods comprise administering to a mammal an effective amount of at least one immunogen selected from the group consisting of: (i) a peptide based on a CDR of the heavy or light chain of an anti-p53 mAb, which peptide is capable of eliciting antibodies to p53; and (ii) a DNA molecule coding for the variable (V) region of an anti-p53 mAb in a suitable gene delivery vehicle. Preferably the immunogen is administered in the form of a pharmaceutical composition. Preferably the peptide is 7 to 30 amino acid residues in length and contains a sequence of the CDR2 or CDR3 of the heavy chain, or of the CDR3 of the light chain of an anti-p53 mAb.

    摘要翻译： 本发明涉及在哺乳动物中诱导抗肿瘤免疫和/或诱导对p53的免疫应答的方法。 所述方法包括向哺乳动物施用有效量的选自以下的至少一种免疫原：（i）基于抗p53mAb的重链或轻链的CDR的肽，所述肽能够引发 p53抗体; 和（ii）在合适的基因递送载体中编码抗p53mAb的可变（V）区的DNA分子。 优选地，免疫原以药物组合物的形式施用。 优选地，肽的长度为7至30个氨基酸残基，并且含有重链的CDR2或CDR3的序列，或抗-p53mAb的轻链的CDR3的序列。

    IMMUNOGENIC COMPOSITIONS FOR INDUCTION OF ANTI-TUMOR IMMUNITY
    8.
    发明申请
    IMMUNOGENIC COMPOSITIONS FOR INDUCTION OF ANTI-TUMOR IMMUNITY 审中-公开
    免疫组织化学诱导抗肿瘤免疫

    公开(公告)号：US20090098116A1

    公开(公告)日：2009-04-16

    申请号：US11943255

    申请日：2007-11-20

    申请人： Irun R. Cohen ,  Varda Rotter ,  Roland Wolkowicz ,  Pedro Ruiz ,  Neta Erez-Alon ,  Johannes Herkel

    发明人： Irun R. Cohen ,  Varda Rotter ,  Roland Wolkowicz ,  Pedro Ruiz ,  Neta Erez-Alon ,  Johannes Herkel

    IPC分类号： A61K39/395 ,  A61K31/711

    CPC分类号： C07K16/30 ,  A61K39/00 ,  A61K2039/505 ,  A61K2039/51 ,  C07K16/18 ,  C07K2317/565 ,  C07K2317/73

    摘要： The invention relates to the use of an immunogen selected from the group consisting of(i) an anti-p53 mAb;(ii) a fragment of an anti-p53 mAb;(iii) a peptide based on a CDR of the heavy or light chain of an anti-p53 mAb, which peptide is capable of eliciting antibodies to p53; and(iv) a DNA molecule coding for the variable (V) region of an anti-p53 mAb in a suitable gene delivery vehicle,for the preparation of a pharmaceutical composition useful for induction of anti-tumor immunity in mammals, for activating an enhanced immune response to a p53 molecule in mammals, and/or for induction of immune responses to mutated and wild-type forms of a p53 in mammals. The use of anti-p53 mAbs and novel peptides based on the CDR2 and CDR3 of the heavy chains and CDR3 of the light chains of different anti-p53 mAbs are disclosed.

    摘要翻译： 本发明涉及选自以下的免疫原的用途：（i）抗p53 mAb; （ii）抗p53 mAb的片段; （iii）基于抗p53 mAb的重链或轻链的CDR的肽，该肽能够引发针对p53的抗体; 和（iv）编码合适的基因递送载体中抗p53mAb的可变（V）区的DNA分子，用于制备用于诱导哺乳动物抗肿瘤免疫的药物组合物，用于激活增强的 对哺乳动物中p53分子的免疫应答，和/或用于诱导哺乳动物中突变​​和野生型形式的p53的免疫应答。 公开了使用抗p53 mAb和基于不同抗p53 mAb的轻链的CDR2和CDR3的CDR3和新型肽。